+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 12Years - 45Years
All Genders
Healthy Volunteers
ID07836452

Study Evaluating Safety and Effects of CITY-RBP4 Injections in Healthy Adults and People With Stargardt Disease Type 1

Led by City Therapeutics · Updated on 2026-09-23

48

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a first-in-human, randomized, double-masked, placebo-controlled clinical study to evaluate the safety, tolerability, and how the body processes and responds to CITY-RBP4 in healthy volunteers and people with Stargardt Disease Type 1 STGD1. The study aims to understand the effects of this investigational drug when given as single and multiple doses under the skin. The study has three parts Part A tests single increasing doses of CITY-RBP4 in healthy adults Part B tests single doses in participants with STGD1 and Part C tests multiple doses in participants with STGD1. Participants receive either CITY-RBP4 or a placebo saline through subcutaneous injections during these phases. Participants will be monitored for up to 360 days to track any adverse effects and to measure how CITY-RBP4 and related substances appear in blood and urine. Safety assessments include eye exams, laboratory tests, and heart monitoring, with emphasis on vision and retinal health. The study involves scheduled visits for dosing and evaluations throughout the treatment and follow-up periods.

CONDITIONS

Brief Title

A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants

Research Team

C

City Therapeutics

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here